Dr Reddys receives EIR from USFDA for Bollaram facility

This indicates the closure of the audit with the inspection classification of the facility determined as Voluntary Action Initiated (VAI).

Oct 09, 2019 06:10 IST India Infoline News Service

Dr Reddys Laboratories informed the exchanges regarding the audit of its API manufacturing plant 2 at Bollaram, Hyderabad

The company said that it has received the Establishment Inspection Report (EIR) from USFDA, for the above-referred facility, indicating closure of the audit and the inspection classification of this facility is determined as Voluntary Action Initiated (VAI).

Dr Reddys Laboratories Ltd is currently trading at Rs2,627.80 up by Rs15.25 or 0.58% from its previous closing of Rs2,612.55 on the BSE.

The scrip opened at Rs2,635 and has touched a high and low of Rs2,666.55 and Rs2,600.10 respectively. So far 2,38,416 (NSE+BSE) shares were traded on the counter. pp

The current market cap of the company is Rs43,406.41cr.


Related Story